Ten years with biologics: to whom do data on effectiveness and safety apply?
2011 (English)In: Rhematology Int, ISSN 1462-0324, E-ISSN 1462-0332, Vol. 50, no 1, 204-213 p.Article in journal (Refereed) Published
The trends in baseline characteristics and drug retention underscores that any effects of biologics, including comparison between different biologics, must be interpreted in light of the characteristics of the population treated. The observed differences further call for continued vigilance to properly evaluate the safety profiles of biologic treatments as they are currently used. Exposure to multiple biologics presents a challenge for attribution of long-term effects.
Place, publisher, year, edition, pages
2011. Vol. 50, no 1, 204-213 p.
Biologics, Rheumatoid arthritis, Anti-tumour necrosis factor, Psoriatic arthritis, Spondylarthritides
IdentifiersURN: urn:nbn:se:umu:diva-45881DOI: 10.1093/rheumatology/keq326PubMedID: 21084326OAI: oai:DiVA.org:umu-45881DiVA: diva2:435637